Areas of interest
Severe and Persistent Pain
- Clinical impact and cost reduction of abuse deterrent formulations and atypical opioids to overall healthcare costs for patients with severe and persistent pain specific to abuse and addiction.
- Process and clinical impact of transitioning patients with severe and persistent pain to alternative therapy options.
- Abuse deterrent formulations and atypical opioids and their impact on healthcare and patient outcomes.
Attention Deficit Hyperactivity Disorder (ADHD)
- Research that further informs the appropriate clinical use of DR/ER-MPH in ADHD, including use in special populations.
- Research with a focus on the abuse deterrent potential of DR/ER-MPH.
Educational grants
Collegium is committed to supporting high quality educational programs through medical education grants. For information on Collegium’s Educational Grant Program, please contact us at: EducationalGrantReviewCommittee@collegiumpharma.com.
investigator initiated studies
Collegium Pharmaceutical is committed to leading with science to provide consistent support to people living with serious medical conditions and the healthcare professionals treating them. Our dedication to following the science is reflected in the support for Investigator Initiated Studies (IIS) that advance medical and scientific knowledge of Collegium Pharmaceutical products and the areas of interest they are designed to treat.
For more information regarding Investigator Initiated Studies (IIS), please contact us at: IISProgram@collegiumpharma.com.